{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T08:30:15Z","timestamp":1724488215790},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2000,6]]},"DOI":"10.1007\/s11864-000-0041-x","type":"journal-article","created":{"date-parts":[[2007,7,26]],"date-time":"2007-07-26T09:14:38Z","timestamp":1185441278000},"page":"281-285","source":"Crossref","is-referenced-by-count":7,"title":["Mantle cell lymphoma"],"prefix":"10.1007","volume":"1","author":[{"given":"John J.","family":"Densmore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"41_CR1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood 1997, 89:390\u2013398.","journal-title":"Blood"},{"key":"41_CR2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, et al.: A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361\u20131392. Pathol Annu 1993,","journal-title":"Blood"},{"key":"41_CR3","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835\u20133849.","journal-title":"J Clin Oncol"},{"key":"41_CR4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0046-8177(95)90090-X","volume":"26","author":"SH Swerdlow","year":"1995","unstructured":"Swerdlow SH, Yang W-I, Zukerberg LR, et al.: Expression of cyclin D1 protein in centrocytic\/mantle cell lymphomas with and without rearrangement of the BCL1\/cyclin D1 gene. Hum Pathol 1995, 26:999\u20131004.","journal-title":"Hum Pathol"},{"key":"41_CR5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","volume":"85","author":"RI Fisher","year":"1995","unstructured":"Fisher RI, Dahlberg S, Nathwani BN, et al.: A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995, 85:1075\u20131082.","journal-title":"Blood"},{"key":"41_CR6","first-page":"115","volume":"36","author":"E Campo","year":"1999","unstructured":"Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Semin Hematol 1999, 36:115\u2013127. An excellent review of the pathologic features, molecular characteristics, and presentation of mantle cell lymphoma, including a summary of prognosis and treatment options.","journal-title":"Semin Hematol"},{"key":"41_CR7","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1997.15.4.1664","volume":"15","author":"A Majlis","year":"1997","unstructured":"Majlis A, Pugh WC, Rodriguez MA, et al.: Mantle cell lymphoma: correlation of clinical outcome and biological features with three histologic variants. J Clin Oncol 1997, 15:1664\u20131671.","journal-title":"J Clin Oncol"},{"key":"41_CR8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","volume":"12","author":"H Samaha","year":"1998","unstructured":"Samaha H, Dumontet C, Ketterer N, et al.: Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998, 12:1281\u20131287.","journal-title":"Leukemia"},{"key":"41_CR9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","volume":"7","author":"P Meusers","year":"1989","unstructured":"Meusers P, Engelhard M, Bartels H, et al..: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989, 7:365\u2013380.","journal-title":"Hematol Oncol"},{"key":"41_CR10","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","volume":"13","author":"I Teodorovic","year":"1995","unstructured":"Teodorovic I, Pittalga S, Kluin-Nelemans JC, et al.: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathological comparisons with 498 other non-Hodgkin\u2019s lymphoma subtypes. J Clin Oncol 1995, 13:2819\u20132826.","journal-title":"J Clin Oncol"},{"key":"41_CR11","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, et al.: Hyper- CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803\u20133809. A trial of high-dose induction chemotherapy followed by autologous or allogeneic stem cell transplantation that demonstrated a higher response rate and improved event-free survival compared with historical controls treated with CHOP-like regimens.","journal-title":"J Clin Oncol"},{"key":"41_CR12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0889-8588(05)70102-7","volume":"13","author":"LJ Johnston","year":"1999","unstructured":"Johnston LJ, Horning SJ: Autologous hematopoietic cell transplantation in non-Hodgkin\u2019s lymphoma. Hematol Oncol Clin North Am 1999, 13:889\u2013918.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"suppl 1","key":"41_CR13","first-page":"172a","volume":"94","author":"P Dreger","year":"1999","unstructured":"Dreger P, Martin S, Kroger N, et al.: The impact of early stem cell transplantation on the prognosis of mantle cell lymphoma. Blood 1999, 94(suppl 1):172a.","journal-title":"Blood"},{"key":"41_CR14","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, et al.: Rituximab for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927\u20131932.","journal-title":"Blood"},{"key":"41_CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZS, Cunningham D, et al.: European phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317\u2013324.","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"41_CR16","first-page":"631a","volume":"94","author":"O Howard","year":"1999","unstructured":"Howard O, Gribben J, Neuberg D, et al.: Rituxan\/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. Blood 1999, 94(suppl 1):631a.","journal-title":"Blood"},{"key":"41_CR17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","volume":"17","author":"JM Foran","year":"1999","unstructured":"Foran JM, Rohatiner AZS, Coiffier B, et al.: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr\u00f6m\u2019s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999, 17:546\u2013553.","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"41_CR18","first-page":"660a","volume":"94","author":"D Inwards","year":"1999","unstructured":"Inwards D, Brown D, Fonseca R, et al.: NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as initial therapy for mantle cell lymphoma: a well-tolerated treatment with promising activity. Blood 1999, 94(suppl 1):660a.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0041-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-000-0041-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0041-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T10:43:14Z","timestamp":1587811394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-000-0041-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11864-000-0041-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]}}}